Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2973777 | Journal of Indian College of Cardiology | 2015 | 9 Pages |
Abstract
This study demonstrated the efficacy and safety of rosuvastatin 5, 10 and 20Â mg starting doses in improving lipid parameters and achieving lipid goals in a heterogeneous group of Indian hyperlipidemic patients in real life clinical practice. In patients with higher cardiovascular risk profile, rosuvastatin 10 and 20Â mg are more effective starting doses for quicker achievement of NCEP-ATP III-defined lipid goals.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Chetan P. Shah, Dayanand K. Kumbla, Asha Moorthy, S. Murthy, Pankaj Aneja, Jagdish Gotur, Anil Gupta, Raman Abhi, Rajeev Bansal, Subhash Sonawala, Anil G. Balani, R. Kedarnathan, Pankaj Soni, P. Chinnaiyan,